Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 (PRNewswire) - Mar 15, 2023 - "Hummingbird Bioscience...announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Meeting 2023....Presentations highlight the robust tumor growth inhibition in preclinical models for its HER3-targeting programs HMBD-001 (HER3 mAb) and HMBD-501 (HER3 ADC). HMBD-001 used as monotherapy or in combination with cetuximab effectively inhibits tumor growth in preclinical squamous cell carcinoma models. HMBD-501 shows superior preclinical efficacy and tolerability compared to other HER3 ADCs across a range of preclinical models, presenting a potentially best-in-class profile."
Preclinical • Oncology • Solid Tumor • Squamous Cell Carcinoma
|